The plasmid DNA manufacturing market to grow at 15% CAGR by 2035, according to a new market research report by Roots Analysis

Published: September 2023


The growing ATMP pipeline has led to an increase in the demand for plasmid DNA, prompting the pharmaceutical stakeholders to either invest in expanding capabilities or outsource the plasmid DNA manufacturing operations

Roots Analysis has announced the addition of Plasmid DNA Manufacturing Market report to its list of offerings.

The plasmid DNA manufacturing process is fraught with several challenges, including low yield, plasmid instability, and regulatory concerns. As a result, researchers and drug developers are increasingly relying on contract service providers with specialized expertise and advanced technologies for their GMP grade plasmid DNA manufacturing requirements. 

To order this 250+ pages report, which features 150+ figures and 160+ tables, please visit https://www.rootsanalysis.com/reports/plasmid-dna-manufacturing-market.html

Key Market Insights 

Over 70 companies claim to offer plasmid DNA services, such as plasmid design, plasmid engineering, plasmid production

Presently, the market is dominated by mid-sized (having 51-500 employees) and small companies (having 11-50 employees). It is worth noting that majority (~60%) of the firms engaged in this domain are based in North America, followed by Europe (~25%).

About 60% of the partnership agreements were inked in the last three years

Manufacturing and supply agreements emerged as the most popular partnership model adopted by stakeholders engaged in this industry, during the period 2015-2023. Further, most of the intercontinental, as well as intracontinental deals have been inked by players based in North America.

Acquisition activity in this domain has increased at a CAGR of 35%, between 2015 and 2022

The maximum number of acquisitions related to plasmid DNA were reported in 2020 (~40%). It is worth highlighting that majority of the acquisitions were done for the purpose of geographical expansion.

Currently, there are more than 70 manufacturing facility dedicated to plasmid DNA production

Nearly 75% of the installed plasmid DNA manufacturing capacity belongs to large and very large players. In addition, 45% of the overall capacity is installed in Asia, followed by North America (30%). 

The growing gene therapy pipeline is anticipated to drive the demand for plasmid DNA, during the forecast period 2023-2035

The commercial demand for plasmid DNA, which forms a vital component of cell and gene therapy products, is projected to increase at a CAGR of ~15.21% during forecast period. Further, the current clinical demand for plasmid DNA captures around 40% of the total demand.

The market is anticipated to grow at a CAGR of around 14.85%, during the forecast period 

By 2035, North America is expected to capture around 45% of the market share, followed by Europe (25%). In terms of therapeutic area, oncological disorders are expected to capture a prominent share of the current and future market.

Key Questions Answered

  • What are the steps in plasmid DNA manufacturing?
  • What is GMP plasmid manufacturing?
  • Who manufactures plasmid DNA?
  • Who are the key players in the plasmid DNA manufacturing market?
  • What is the size of the plasmid manufacturing market?
  • What are the leading market segments in the plasmid DNA manufacturing market? 
  • Which region has the highest market share in plasmid DNA manufacturing market?
  • What is the plasmid DNA manufacturing market growth?
  • What are the factors driving the plasmid DNA manufacturing market?
  • What are the upcoming trends in the plasmid DNA manufacturing market?

The financial opportunity within the plasmid DNA manufacturing market has been analyzed across the following segments:

  • Scale of Operation 
    • Commercial 
    • Clinical
    • Preclinical 
  • Grade of Plasmid DNA
    • GMP Grade Plasmid DNA 
    • High Quality Plasmid DNA
    • Research Grade Plasmid DNA
  • Application Area 
    • Cell Therapy Manufacturing
    • DNA Vaccine Development 
    • Gene Therapy Manufacturing
    • mRNA Therapy Development
    • Viral Vector Manufacturing
  • Therapeutic Area 
    • Infectious Diseases
    • Oncological Disorders 
    • Genetic Disorders 
    • Others
  • End User 
    • Pharma / Biotech Companies
    • Academic and Research Institutes
    • Others
  • Geography
    • North America
    • Europe
    • Asia
    • Latin America
    • Middle East and North Africa 
    • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom, growing demand for gene therapy products and increasing trend of outsourcing will drive the growth of third-party service providers engaged in the plasmid DNA manufacturing market, The report includes detailed transcripts of the discussions held with following industry experts:

The research also includes detailed profiles of key players (listed below), featuring a brief overview of the company, details related to its financial information (if available), recent developments (including partnerships and collaborations) and an informed future outlook.

  • AGC Biologics 
  • Aldevron
  • Biomay
  • Catalent Pharma Solutions
  • Charles River 
  • Cytovance Biologics
  • Forge Biologics
  • GenScript ProBio
  • Thermo Fisher Scientific
  • VGXI

For additional details, please email at sales@rootsanalysis.com 

You may also be interested in the following titles:

  1. Single Use Bioreactors Market
  2. Allogeneic Cell Therapy Market
  3. Patient Engagement Solutions Market
  4. Antibody Drug Conjugate Market
  5. Adeno-Associated Viral Vectors / AAV Vector Market

Contact:

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry